imiquimod


Also found in: Dictionary, Wikipedia.

imiquimod

 [im″ĭ-kwim´od]
a biologic response modifier used topically in the treatment of venereal warts of the external genitalia and perianal region.

i·mi·qui·mod

(im'i-kwī'mod),
An immune response modifier used on the skin in the treatment of external genital and perianal warts.

imiquimod

/im·i·quim·od/ (im″ĭ-kwim´od) a biologic response modifier used topically in the treatment of condyloma acuminatum.

imiquimod

[im′ĭkwim′od]
a biological response modifier used topically in the treatment of venereal warts of the external genitalia and perianal region.

imiquimod

a topical immune response modifier with antiviral and antineoplasia effects. Used in veterinary medicine to treat squamous cell carcinomas and viral papillomas.
References in periodicals archive ?
Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumors.
Two separate studies have indicated that 75%-80% of subjects achieve complete clearing after an initial 16-week course of imiquimod; 59%-75% of recurrences will clear with another 16-week course of treatment with imiquimod.
Most local skin side effects to imiquimod are mild to moderate and include erythema (redness), erosion, flaking, edema (swelling), scabbing, and induration (hardening) at the wart site.
Before ingenol mebutate came on the market, investigators randomized patients with AKs to one of three treatment groups: imiquimod 5% cream, 5-FU 5% ointment, or cryotherapy (Br.
The study measured overall survival, disease control rate, T-cell responses to IMA910, the effect of imiquimod on immune response, the association of immune response with clinical benefit, and safety and tolerability.
of the University of Minnesota, Minneapolis, utilized pharmacoeconomic modeling based upon data from the two pivotal phase III, double-blind, vehicle-controlled, randomized trials of sinecatechins ointment 15% (Veregen), along with a systematic review of the published imiquimod (Aldara) literature, Dr.
Angiolymphoid hyperplasia with eosinophilia successfully treated with imiquimod.
Researchers found that imiquimod produced good results for patients when used together with surgery to treat the cancer, potentially helping doctors cut less.
In this issue of the Southern Medical Journal, Yuchi Chang and Stephen Tyring present an interesting review of the dermatologic product imiquimod (Aldara, 3M Pharmaceuticals) in their article "Current and Potential Uses of Imiquimod".
Granuloma annulare resolved with topical application of imiquimod.
Bettencourt said that the gel offers cosmetic advantages over other treatments such as the topical imiquimod or photodynamic therapy because there is no hypo- or hyperpigmentation.